Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 3
2018 6
2019 13
2020 15
2021 26
2022 15
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean takuhiro yamaguchi (336 results)?
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Takeda M, et al. Among authors: yamaguchi k. Lung Cancer. 2023 Mar;177:44-50. doi: 10.1016/j.lungcan.2023.01.011. Epub 2023 Jan 28. Lung Cancer. 2023. PMID: 36731290 Free article. Clinical Trial.
Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan.
Omori K, Kitagawa H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Tadera K, Nomura T, Shigemoto N, Aoki G, Hattori N, Ohge H. Omori K, et al. Among authors: yamaguchi k. J Infect Chemother. 2023 Sep;29(9):875-881. doi: 10.1016/j.jiac.2023.05.013. Epub 2023 May 19. J Infect Chemother. 2023. PMID: 37209842
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: yamaguchi k. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, Nishii K, Shoda H, Yamaguchi K, Kawakado K, Toyoda Y, Inoue M, Miyatake N, Watanabe N, Inoue T, Mizoguchi H, Komori Y, Kojima K, Kadowaki N. Kanaji N, et al. Among authors: yamaguchi k. Lung. 2024 Feb;202(1):63-72. doi: 10.1007/s00408-023-00669-9. Epub 2024 Jan 24. Lung. 2024. PMID: 38265672 Free PMC article.
79 results